Regeneron Pharmaceuticals was a leading decliner within the health care sector, falling $4.05 (-1.6%) to $245.96 on light volume

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals ( REGN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.5%. By the end of trading, Regeneron Pharmaceuticals fell $4.05 (-1.6%) to $245.96 on light volume. Throughout the day, 488,012 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 817,000 shares. The stock ranged in price between $242.84-$249.15 after having opened the day at $248.59 as compared to the previous trading day's close of $250.01. Other companies within the Health Care sector that declined today were: Biota Pharmaceuticals ( BOTA), down 62.7%, Vical Incorporated ( VICL), down 57.3%, Mast Therapeutics ( MSTX), down 41.4% and Inovio Pharmaceuticals ( INO), down 21.4%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $24.4 billion and is part of the drugs industry. Shares are up 46.1% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.